Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9615 posts found.

Sandoz biosimilars as safe and efficacious as originators, says early trials data

June 9, 2016 Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab

Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
News

AstraZeneca sells rights to anaesthetics products to Aspen for $520 million upfront

June 9, 2016 Research and Development, Sales and Marketing AstraZeneca, Licencing, anaesthetics, aspen, marketing agreement

UK drug firm AstraZeneca (LSE: AZN) on Thursday said it has agreed to sell rights for its anaesthetics portfolio to Aspen …
News
samsung

New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016

June 8, 2016 Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5

Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
News
cipla

India-based Cipla gets new chief financial officer

June 8, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cipla, Dr Reddy's, cfo, dr reddys

Cipla (NSE: CIPLA) has poached a top executive from Dr. Reddy’s by naming Kedar Upadhye as its new global chief …
Appointment
novartis_side_building

Novartis to compare Cosentyx with Humira in new clinical trials

June 8, 2016 Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016

Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …
News
biogen_austria_238

Biogen MS drug misses primary endpoint in Phase II trial

June 8, 2016 Research and Development Biogen, MS, multiple sclerosis, opicinumab

Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …
News
stocks3

Losses and profit forecast cuts send shares tumbling again at Valeant

June 8, 2016 Research and Development, Sales and Marketing Shares, Valeant, cut, forecast, tumbling

Valeant Pharmaceuticals has published its results for the first quarter, which has seen the firm post a net loss of …
News

Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment

June 8, 2016 Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer

Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …
News
msd

MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival

June 8, 2016 Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda

Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
News
merckwindow

MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility

June 7, 2016 Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth

MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …
News
ascologo

Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study

June 7, 2016 Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social

Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …
Feature
clinical_trial_4

The Pharmafocus ASCO round-up

June 7, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus

As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …
Feature
astrazeneca_plaque

AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer

June 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
News
gavel

Judge reverses verdict in MSD/Gilead hepatitis C dispute

June 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi

A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
News
allergan

FDA approves Allergan hypertension fixed-dose combo, Byvalson

June 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan

Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …
News
The Gateway to Local Adoption Series

Latest content

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026

Ofichem brings all brands under single trading name

April 23, 2026